All articles tagged with #neurodegeneration
Yale researchers identified two neuron surface proteins, mGluR4 and NPDC1, that help misfolded α-synuclein enter healthy neurons and drive Parkinson's progression; genetically blocking either protein in mice reduced spread and symptoms, pointing to a new therapeutic target to slow the disease.
A Texas A&M study used Theiler's murine encephalomyelitis virus (TMEV) in mice to model Parkinson's-like neurodegeneration. The virus infected dopamine-producing neurons and caused motor deficits that persisted after the virus was cleared, suggesting viruses could contribute to Parkinson's risk alongside genetic or environmental factors. This new viral model offers a tool to study disease progression and etiology, complementing genetic or toxin-based models, though TMEV itself does not infect humans.
Scientists have identified karyoptosis as a key mechanism by which brain cells die in Alzheimer's disease and frontotemporal dementia. The process involves nuclear shrinkage and breakdown triggered by toxic protein buildup; blocking the p38 MAP kinase-LaminB1 interaction in neuron cultures reduced markers of this death pathway, offering a potential new target to slow neuron loss and progression of dementia.
Scientists identify a conserved region (CR; residues 320–340) in TDP-43's low-complexity domain as a drug target. Deleting CR or treating with XL20, a brain-penetrant molecule that binds CR, dampens TDP-43 toxicity, corrects mitochondria-related dysfunction via LLPS, and prolongs survival in ALS mouse models, with positive effects in human mutant TDP-43 motor neurons, all while preserving TDP-43 splicing. XL20 shows CNS penetration and good safety, supporting CR targeting as a therapeutic strategy for TDP-43–related neurodegeneration.
A UCLA-led study found long-term residential exposure to the pesticide chlorpyrifos is linked to more than a 2.5-fold increase in Parkinson’s disease risk. Lab experiments in mice and zebrafish suggest chlorpyrifos damages dopamine neurons by disrupting autophagy, offering insight into the disease mechanism and potential therapeutic targets and underscoring the need for monitoring exposed individuals.
A Salk Institute study reveals that long-term iron buildup in neurons—rather than brief exposure—gradually erodes antioxidant defenses and elevates lipid peroxidation, triggering chronoferroptosis, a time-dependent stress pathway that leaves neurons vulnerable to stress and points to new preventive therapies to combat neurodegenerative diseases.
New research hints that cannabinol, a byproduct of THC, may protect brain cells from oxidative stress and potentially reduce dementia risk, but findings are preliminary and not conclusive; other studies show older adults starting medical cannabis may not experience significant cognitive decline, while concerns about teen use and psychiatric risks persist, leaving the overall impact of cannabis on aging brains unresolved.
ETH Zurich researchers identify inactive GRK2 aggregates that disrupt mitochondrial energy and drive amyloid beta buildup in Alzheimer’s, forming a damaging feedback loop. They developed Compound 10, which blocks GRK2 aggregation, preserves mitochondrial function, reduces amyloid beta, and slows nerve-cell loss in mice, suggesting a new upstream therapeutic approach that could complement existing treatments; a patent has been filed and industry partnerships are being pursued.
UF Health analyzed records from 2012–2024 plus brain tissue and mouse studies and found glucosamine use associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia and a 25% higher mortality in Alzheimer's disease patients. The research points to a hyperactive protein sugar-tagging (glycosylation) pathway as a potential mechanism, suggesting metabolic dysfunction may drive progression, though causality isn’t proven and clinical trials are needed.
Japanese researchers developed vitamin K analogs linked to retinoic acid that threefold boost the differentiation of neural progenitor cells into neurons and cross the blood–brain barrier in mice, increasing brain MK-4 levels; this points to a regenerative approach for diseases like Alzheimer's and Parkinson’s, though human trials are not yet underway.
Scientists developed a tool to temporarily boost mitochondrial activity in the brain, and in mouse models of neurodegenerative disease this restored memory performance, suggesting energy failure in neurons may drive cognitive decline and could become a new therapeutic target—though the approach is still far from human use and requires extensive safety and efficacy studies.
A Baylor College of Medicine study suggests increasing cellular tubulin can steer Tau and alpha-synuclein away from harmful aggregates toward healthy microtubule activity, offering a potential therapeutic strategy for Alzheimer’s and Parkinson’s by boosting tubulin rather than blocking condensate formation.
A study of 1,647 middle-aged and older adults found that closer adherence to the MIND diet—a Mediterranean-DASH blend rich in antioxidants—was linked to less brain tissue loss, especially gray matter, and less ventricular enlargement over about 12 years, equating to roughly 2.5 years slower brain aging; results varied with some foods (whole grains linked to faster gray-matter decline; cheese linked to slower decline), and causality isn’t established.
Researchers at Heidelberg and Shandong University identified a toxic interaction between NMDA receptors and the TRPM4 channel—described as a 'death complex'—that worsens Alzheimer’s in a mouse model. They showed FP802, a novel neuroprotective drug, can block this interaction, slowing neurodegeneration, preserving synapses and mitochondria, and reducing amyloid deposits, offering a therapeutic approach distinct from amyloid removal. While promising, further pharmacological development, toxicology work, and clinical trials are needed before it could be used in humans, and researchers are also exploring potential ALS applications.
A new study suggests Alzheimer's may start when amyloid beta competes with tau for binding to microtubules in neurons, displacing tau and destabilizing the cell’s transport system. This microtubule nexus could unify amyloid- and tau-centered theories and open pathways for therapies that target tau displacement from microtubules.